POWER THE COURSE OF FIGHTING DISEASES AND SAVING LIVES
Domain expertise, global resource, long-term capital
PORTFOLIO NEWS
September 11, 2019HONG KONG, Sept. 10, 2019 /PRNewswire/ -- Insilico Medicine, a pioneer in next-generation...September 4, 2019- Proceeds to support continued development of robust portfolio of AAV-delivered therapeutics...September 3, 2019-INBRX-109 was well-tolerated; a maximum tolerated dose was not reached- -INBRX-109 demonstrated...Adds Novel Bio-Activated Pharmaceuticals to Glaukos’ New Corneal Health Franchise Potential...Cambridge, MA and Shanghai — July 16, 2019 — X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical...FOSTER CITY, CA, and SHANGHAI, June 24th, 2019 – Terns Pharmaceuticals, Inc. today announced an...June 18, 2019Jacobio’s SHP2 inhibitor (JAB-3068) independently developed by Jacobio Pharmaceuticals Co., Ltd....May 29, 2019INDIANAPOLIS, May 28, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced a...More Posts
Company
Shanghai
Room2909-14, 168 Hubin Road, Huangpu District, Shanghai, China.
Hong Kong
Unit 902-904, Two ChinaChem Central, 26 Des Voeux Road Central, Hong Kong
US
2730 Sand Hill Road, Suite 130, Menlo Park, CA
All Posts
×
LillyAsiaVentures
Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm headquartered in China, with offices in Shanghai, Hong Kong, and Palo Alto.
http://user-assets.sxlcdn.com/images/315509/FnksTvTDur7jpExbqYminmtjWgoM.png?imageMogr2/strip/auto-orient/thumbnail/1200x630>/format/png